Wordt geladen...
Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy
We report our experience with the use of intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). A retrospective review was performed on 138 consecutive infants screened at a single centre over 18 months. Intravitreal ranibizumab was offered in selected cases requiring treatm...
Bewaard in:
| Gepubliceerd in: | Sci Rep |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4891718/ https://ncbi.nlm.nih.gov/pubmed/27256987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep27082 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|